A Phase 3 interventional study of dronabinol and ondansetron in Chemotherapy Induced Nausea and Vomiting, sponsored by Solvay Pharmaceuticals. Completed at 43 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-04-03.
Sponsored by Solvay Pharmaceuticals (part of Abbott) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 286 studies in Vomiting with a site in United States — 26 open to participants now, 29 under way, 5 of them phase 3. Vomiting · United States.
Among the 286 studies in Vomiting with a site in United States, this one is the 144th largest by enrollment of the 256 interventional ones that give a count, is one of 9 that started in 2003, is one of 48 in phase 3, and was the 68th registered.
794 studies on the registry are indexed under Vomiting; 99 are open to participants now.
Browse Vomiting studies →26 of the 286 studies in Vomiting with a site in United States are open now. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States
Ages 18–65 · Healthy volunteers
University of Southern California · Sites in United States
Ages 18–49 · Women only · Healthy volunteers
Vanda Pharmaceuticals · Sites in United States
Ages 18–65 · Healthy volunteers
David Levinthal · Sites in United States
Ages 21–60 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Australia, China and 7 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
286 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 68 · Phase 3 54 · Phase 4 34
First in 1999; this study’s year is marked. 9 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 103 across 674 interventional studies indexed under Vomiting.
Median enrollment 89 across the 256 interventional studies, 64 across the 25 observational. Of the 230 that completed or were terminated, 121 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 286 have an industry lead sponsor. The 10 most frequent:
This study is registered under Solvay Pharmaceuticals, one of the names counted as Abbott. Under that name alone:
Solvay Pharmaceuticals is the lead sponsor of 86 studies on the registry; none are open to participants now.
Abbott has 3 studies filed under Vomiting — fewer than ten, so there is no comparison to draw.
15 of the studies in Vomiting with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07446439Phase 3Vanda PharmaceuticalsA Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | 2026-12-01 |
| NCT06382012Phase 3Montefiore Medical CenterAntiemetic Fosaprepitant To Remedy Nausea and Vomiting | 2027-03 |
| NCT05418244Phase 3State University of New York at BuffaloInhaled Isopropyl Alcohol for Treatment of Nausea | 2027-06-30 |
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
Add all 15 to your calendar (.ics) → With an account.
Among the 286 studies in Vomiting with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting (CINV) or retching by measuring the incidence of total response of nausea and vomiting and/or retching following administration of moderate-to-high emetogenic chemotherapeutic agents.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Undergoing single or multiple days of chemotherapy as long as Day 1 chemotherapy includes:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: dronabinol
Drug: ondansetron
Drug: dronabinol/ondansetron
Drug: placebo
10 - 20 mg
8 - 16 mg
Drug pages: Dronabinol · Ondansetron
10 - 20 mg/8 - 16 mg
placebo
Total response of nausea and vomiting/retching was defined as no vomiting and/or retching, an intensity of nausea of < 5 mm on the visual analog scale (VAS) and no use of rescue medication.
Time frame: 5 days
Complete responder rate (no vomiting/retching, intensity of nausea of ≤ 30 mm on the VAS and no use of rescue medication)
Time frame: 5 days
Presence or absence of nausea
Time frame: 5 days
Episodes of vomiting and/or retching
Time frame: 5 days
Duration of nausea and vomiting and/or retching
Time frame: 5 days
The record gives a start of Jul 2003, a primary completion of Jul 2004 and a completion of Jul 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dronabinol